CLN5 and prostate cancer: During this phase, prostate cancer cells induce a dysfunctional osteoblastic phenotype, through the production of factors including BMPs, TGF-β, PDGF, adrenomedullin, IGF-1, FGF, and vascular endothelial growth factor (VEGF).